Timothy Pluard

Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)

William M. Sikov, Donald A. Berry, Charles M. Perou et al. · Journal of Clinical Oncology · 2014 · 1K citations · Full text

Medicine, Oncology, Pharmacology +17

Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts

Shunqiang Li, Dong Shen, Jieya Shao et al. · Cell Reports · 2013 · 625 citations · Full text

Medicine, Genetics, Oncology +14

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma

Linda M. Liau, Keyoumars Ashkan, David D. Tran et al. · Journal of Translational Medicine · 2018 · 540 citations · Full text

Medicine, Immunology, Oncology +17

Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)

Matthew J. Ellis, Vera J. Suman, Jeremy Hoog et al. · Journal of Clinical Oncology · 2017 · 411 citations · Full text

Medicine, Oncology, Pharmacotherapy +17